AstraZeneca’s (AZN) Respiratory segment is one its key growth platforms. The segment reported nearly flat revenue of $1.2 billion at constant exchange rates in 1Q17.
The products included in this segment are Symbicort, Pulmicort, Daliresp, Tudorza, and Duaklir.
Symbicort is a drug used for the prevention of bronchospasm. Symbicort’s revenue fell 8% at constant exchange rates to $677 million in 1Q17. At constant exchange rates, it reported a 21% fall in US sales and a 9% fall in European sales, partially offset by a 10% rise in emerging market sales.
Pulmicort, a drug for the prevention of the asthma attacks, reported a revenue rise of 14% at constant exchange rates to $337 million in 1Q17. This rise was driven by a 28% rise in emerging market revenue and an 11% rise in revenue from rest of the world. The rise was substantially offset by lower sales in US and European markets.
Other drugs in AZN’s Respiratory segment include Daliresp, Tudorza/Eklira, and Duaklir. Eklira and Duaklir were added to AstraZeneca’s portfolio following its deal with Almirall. AstraZeneca acquired Tudorza and Daliresp from Allergan (AGN).
Daliresp reported a revenue rise of 42% to $44 million in 1Q17, while Tudorza/Eklira reported a 3% revenue fall to $37 million in 1Q17. The drug Duaklir reported a 54% revenue rise in 1Q17 to $19 million due to strong growth in European markets.
To divest risk, investors can consider ETFs such as the Vanguard Total International Stock ETF (VXUS), which holds 0.4% of its total assets in AstraZeneca.